Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Is fondaparinux safer than enoxaparin for patients undergoing percutaneous coronary intervention?

Nature Clinical Practice Cardiovascular Medicine volume 5, pages 184–185 (2008)Cite this article

boxed-textMehta SR et al. (2007) Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. J Am Coll Cardiol 50: 1742–1751

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Yusuf S et al. for the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (2006) Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 354: 1464–1476

    Article  CAS  Google Scholar 

  2. Anderson JL et al. (2007) ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 50: e1–e157

    Article  Google Scholar 

  3. Bassand JP et al. for the Task Force for Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of European Society of Cardiology (2007) Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 28: 1598–1660

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Alexandra King, Associate Editor, Nature Clinical Practice.

Author information

Author notes

  1. Brigham and Women's Hospital, Cardiovascular Division, 75 Francis Street, Boston, MA 02115, USA eantman@partners.org

Authors and Affiliations

  1. EM Antman is the Director of the Samuel A Levine Cardiac Unit at the Brigham and Women's Hospital and Professor of Medicine at Harvard Medical School, Boston, MA, USA.,

    Elliott M Antman

Authors
  1. Elliott M Antman
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

EM Antman has received funding of less than US $10,000 for studies coordinated by the TIMI Study Group, but where he was not the principle investigator, from the following companies: Accumetrics, Amgen, AstraZeneca, Bayer, Beckman Coulter, Biosite, Bristol-Myers Squibb, CV Therapeutics, GlaxoSmithKline, Inotek Pharmaceuticals, Integrated Therapeutics, Merck & Co., Millennium Pharmaceuticals, NIH, Novartis, Nuvelo, Ortho-Clinical Diagnostics, Pfizer, Roche Diagnostics, Sanofi Synthelabo, and Schering-Plough. Dr Antman has received funding of more than US $10,000 for studies coordinated by the TIMI Study Group where he was the principle investigator from the following companies: Daiichi Sankyo, Eli Lilly and Company, and Sanofi Synthelabo.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Antman, E. Is fondaparinux safer than enoxaparin for patients undergoing percutaneous coronary intervention?. Nat Rev Cardiol 5, 184–185 (2008). https://doi.org/10.1038/ncpcardio1151

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpcardio1151

This article is cited by

  • Fondaparinux Sodium

    • Stephanie K. A. Blick
    • Jennifer S. Orman
    • Lesley J. Scott

    American Journal of Cardiovascular Drugs (2008)

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing